ARWR
Price
$12.06
Change
-$0.63 (-4.96%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
1.66B
35 days until earnings call
ATYR
Price
$2.78
Change
-$0.18 (-6.08%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
263.02M
34 days until earnings call
Ad is loading...

ARWR vs ATYR

Header iconARWR vs ATYR Comparison
Open Charts ARWR vs ATYRBanner chart's image
Arrowhead Pharmaceuticals
Price$12.06
Change-$0.63 (-4.96%)
Volume$31.32K
Capitalization1.66B
aTyr Pharma
Price$2.78
Change-$0.18 (-6.08%)
Volume$17.61K
Capitalization263.02M
ARWR vs ATYR Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. ATYR commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and ATYR is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARWR: $12.69 vs. ATYR: $2.96)
Brand notoriety: ARWR: Notable vs. ATYR: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 102% vs. ATYR: 78%
Market capitalization -- ARWR: $1.66B vs. ATYR: $247.03M
ARWR [@Biotechnology] is valued at $1.66B. ATYR’s [@Biotechnology] market capitalization is $247.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileATYR’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • ATYR’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than ATYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while ATYR’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 4 bearish.
  • ATYR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than ATYR.

Price Growth

ARWR (@Biotechnology) experienced а -8.90% price change this week, while ATYR (@Biotechnology) price change was -8.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

ARWR is expected to report earnings on May 08, 2025.

ATYR is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($1.66B) has a higher market cap than ATYR($263M). ATYR YTD gains are higher at: -18.232 vs. ARWR (-32.500). ATYR has higher annual earnings (EBITDA): -66.37M vs. ARWR (-580.69M). ARWR has more cash in the bank: 553M vs. ATYR (72.1M). ATYR has less debt than ARWR: ATYR (13.3M) vs ARWR (525M). ARWR has higher revenues than ATYR: ARWR (2.5M) vs ATYR (235K).
ARWRATYRARWR / ATYR
Capitalization1.66B263M630%
EBITDA-580.69M-66.37M875%
Gain YTD-32.500-18.232178%
P/E RatioN/AN/A-
Revenue2.5M235K1,064%
Total Cash553M72.1M767%
Total Debt525M13.3M3,947%
FUNDAMENTALS RATINGS
ARWR vs ATYR: Fundamental Ratings
ARWR
ATYR
OUTLOOK RATING
1..100
5458
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9352
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATYR's Valuation (81) in the null industry is in the same range as ARWR (96) in the Biotechnology industry. This means that ATYR’s stock grew similarly to ARWR’s over the last 12 months.

ATYR's Profit vs Risk Rating (100) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that ATYR’s stock grew similarly to ARWR’s over the last 12 months.

ATYR's SMR Rating (98) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that ATYR’s stock grew similarly to ARWR’s over the last 12 months.

ATYR's Price Growth Rating (52) in the null industry is somewhat better than the same rating for ARWR (93) in the Biotechnology industry. This means that ATYR’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ATYR (100) in the null industry. This means that ARWR’s stock grew significantly faster than ATYR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRATYR
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 22 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JANBX44.920.15
+0.34%
Janus Henderson Balanced D
BRXUX13.890.03
+0.22%
MFS Blended Research Intl Eq R4
SEIRX16.28N/A
N/A
SEI Real Estate I (SIMT)
MAISX19.77N/A
N/A
Victory Integrity Small/Mid-Cap Value A
GAOFX20.09N/A
N/A
JPMorgan Global Allocation R4

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
+2.78%
MGTX - ATYR
43%
Loosely correlated
+3.25%
NTLA - ATYR
36%
Loosely correlated
+9.69%
SLDB - ATYR
35%
Loosely correlated
+7.11%
ARWR - ATYR
34%
Loosely correlated
+3.97%
AMLX - ATYR
34%
Loosely correlated
+13.17%
More